News
A study by IDIBELL and Bellvitge University Hospital identifies iron deficiency as a key element in the progression of heart failure
The study, published on Cell & Bioscience, includes two experimental approaches, one with mice and the other one with cell cultures. This discovery may be the basis for the development of better treatments for this disease and means a paradigm shift.
New chair to promote research in precision radiation oncology
Today, the UB and the biomedical company Atrys Health, specialized in precision medicine, have signed a collaboration agreement to create the Personalized Radiotherapy Chair, which will be led by Ferran Guedea, head of the IDIBELL Radiobiology and Cancer Group.
Five IDIBELL’s projects receive funding from La Marató 2020 dedicated to COVID-19
IDIBELL will receive almost 630,000 euros from La Marató de TV3 and Catalunya Radio to carry out five projects. The funded studies will focus on the research of factors to predict COVID-19 complications and testing vaccines in vulnerable patients.
IDIBELL researchers participate in a study that describes a new mechanism of resistance to hepatocellular carcinoma treatment
Identification of the miR-518d-5p molecule in blood is associated with increased resistance to sorafenib treatment and reduced overall survival in patients with hepatocellular carcinoma
Science and performing arts against stereotypes
A study by IDIBELL and UB shows that participation in a workshop combining scientific training and theatre performance reduces implicit biases against physical illnesses
Exercise prevents neuronal damage caused by lung cancer treatment
A study of IDIBELL, ICO, and Bellvitge University Hospital shows that exercise not only prevents the loss of neuronal tissue caused by chemotherapy and radiotherapy. Also, patients who follow sports guidelines increase the volume of gray matter in the brain regions involved in memory and learning functions, such as the hippocampus.
The definition of the metabolic characteristics of breast cancer opens the door to new therapeutic strategies
An international study, with the participation of IDIBELL and ICO, determines that the metabolism of breast tumor cells is defined by their origin.
A new study about the reprogramming of lipid metabolism to combat cellular hepatocarcinoma
A work coordinated by Isabel Fabregat – group leader of TGF-β and Cancer group at IDIBELL and CIBEREHD – University of Barcelona – studies the reprogramming of lipid metabolism and provides new perspectives for the possible use of fatty acids and mitochondrial oxidative metabolism in new pharmacological approaches to decrease the metastasis of hepatocellular carcinoma.
A mouse model to predict the response to the treatment of a myeloma patient
Researchers from IDIBELL and ICO have used an orthotopic mouse model to expand the myeloma patient’s tumor tissue to study his molecular characteristics and response to different treatments.